[1] |
GRACIA-SANCHO J, MARRONE G, FERNÁNDEZ-IGLESIAS A. Hepatic microcirculation and mechanisms of portal hypertension[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(4): 221-234. DOI: 10.1038/s41575-018-0097-3.
|
[2] |
TSOCHATZIS EA, BOSCH J, BURROUGHS AK. Liver cirrhosis[J]. Lancet, 2014, 383(9930): 1749-1761. DOI: 10.1016/S0140-6736(14)60121-5.
|
[3] |
XU XY, DING HG, LI WG, et al. Chinese guidelines on the management of liver cirrhosis (abbreviated version)[J]. World J Gastroenterol, 2020, 26(45): 7088-7103. DOI: 10.3748/wjg.v26.i45.7088.
|
[4] |
EL-SHERIF O, JIANG ZG, TAPPER EB, et al. Baseline factors associated with improvements in decompensated cirrhosis after direct-acting antiviral therapy for hepatitis C virus infection[J]. Gastroenterology, 2018, 154(8): 2111-2121.e8. DOI: 10.1053/j.gastro.2018.03.022.
|
[5] |
de FRANCHIS R, Baveno VI Faculty. Expanding consensus in portal hypertension: Report of the Baveno Ⅵ Consensus Workshop: Stratifying risk and individualizing care for portal hypertension[J]. J Hepatol, 2015, 63(3): 743-752. DOI: 10.1016/j.jhep.2015.05.022.
|
[6] |
D'AMICO G, GARCIA-TSAO G, PAGLIARO L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies[J]. J Hepatol, 2006, 44(1): 217-231. DOI: 10.1016/j.jhep.2005.10.013.
|
[7] |
ARVANITI V, D'AMICO G, FEDE G, et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis[J]. Gastroenterology, 2010, 139(4): 1246-1256.e1-5. DOI: 10.1053/j.gastro.2010.06.019.
|
[8] |
FEDE G, D'AMICO G, ARVANITI V, et al. Renal failure and cirrhosis: a systematic review of mortality and prognosis[J]. J Hepatol, 2012, 56(4): 810-818. DOI: 10.1016/j.jhep.2011.10.016.
|
[9] |
D'AMICO G, PASTA L, MORABITO A, et al. Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients[J]. Aliment Pharmacol Ther, 2014, 39(10): 1180-1193. DOI: 10.1111/apt.12721.
|
[10] |
D'AMICO G, MORABITO A, D'AMICO M, et al. New concepts on the clinical course and stratification of compensated and decompensated cirrhosis[J]. Hepatol Int, 2018, 12(Suppl 1): 34-43. DOI: 10.1007/s12072-017-9808-z.
|
[11] |
MOREAU R, JALAN R, GINES P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis[J]. Gastroenterology, 2013, 144(7): 1426-1437.e1-e9. DOI: 10.1053/j.gastro.2013.02.042.
|
[12] |
TREBICKA J, FERNANDEZ J, PAPP M, et al. The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology[J]. J Hepatol, 2020, 73(4): 842-854. DOI: 10.1016/j.jhep.2020.06.013.
|
[13] |
COSTA D, SIMBRUNNER B, JACHS M, et al. Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality[J]. J Hepatol, 2021, 74(4): 819-828. DOI: 10.1016/j.jhep.2020.10.004.
|
[14] |
ARROYO V, ANGELI P, MOREAU R, et al. The systemic inflammation hypothesis: Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis[J]. J Hepatol, 2021, 74(3): 670-685. DOI: 10.1016/j.jhep.2020.11.048.
|
[15] |
JACHS M, HARTL L, SCHAUFLER D, et al. Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes[J]. Gut, 2021, 70(9): 1758-1767. DOI: 10.1136/gutjnl-2020-322712.
|
[16] |
D'AMICO G, BERNARDI M, ANGELI P. Towards a new definition of decompensated cirrhosis[J]. J Hepatol, 2022, 76(1): 202-207. DOI: 10.1016/j.jhep.2021.06.018.
|
[17] |
BALCAR L, SEMMLER G, POMEJ K, et al. Patterns of acute decompensation in hospitalized patients with cirrhosis and course of acute-on-chronic liver failure[J]. United European Gastroenterol J, 2021, 9(4): 427-437. DOI: 10.1002/ueg2.12089.
|
[18] |
KIM TH, UM SH, LEE YS, et al. Determinants of re-compensation in patients with hepatitis B virus-related decompensated cirrhosis starting antiviral therapy[J]. Aliment Pharmacol Ther, 2022, 55(1): 83-96. DOI: 10.1111/apt.16658.
|
[19] |
XU X, WANG H, ZHAO W, et al. Recompensation factors for patients with decompensated cirrhosis: a multicentre retrospective case-control study[J]. BMJ Open, 2021, 11(6): e043083. DOI: 10.1136/bmjopen-2020-043083.
|
[20] |
JU YC, JUN DW, CHOI J, et al. Long term outcome of antiviral therapy in patients with hepatitis B associated decompensated cirrhosis[J]. World J Gastroenterol, 2018, 24(40): 4606-4614. DOI: 10.3748/wjg.v24.i40.4606.
|
[21] |
ZHAO H, WANG Q, LUO C, et al. Recompensation of decompensated hepatitis B cirrhosis: Current status and challenges[J]. Biomed Res Int, 2020, 2020: 9609731. DOI: 10.1155/2020/9609731.
|
[22] |
de FRANCHIS R, BOSCH J, GARCIA-TSAO G, et al. Baveno Ⅶ - Renewing consensus in portal hypertension[J]. J Hepatol, 2022, 76(4): 959-974. DOI: 10.1016/j.jhep.2021.12.022.
|
[23] |
D'AMBROSIO R, AGHEMO A, RUMI MG, et al. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis[J]. Hepatology, 2012, 56(2): 532-543. DOI: 10.1002/hep.25606.
|
[24] |
BEDOSSA P. Reversibility of hepatitis B virus cirrhosis after therapy: who and why?[J]. Liver Int, 2015, 35(Suppl 1): 78-81. DOI: 10.1111/liv.12710.
|
[25] |
THEISE ND, JIA J, SUN Y, et al. Progression and regression of fibrosis in viral hepatitis in the treatment era: the Beijing classification[J]. Mod Pathol, 2018, 31(8): 1191-1200. DOI: 10.1038/s41379-018-0048-0.
|
[26] |
HSU SJ, TSAI MH, CHANG CC, et al. Extrahepatic angiogenesis hinders recovery of portal hypertension and collaterals in rats with cirrhosis resolution[J]. Clin Sci (Lond), 2018, 132(6): 669-683. DOI: 10.1042/CS20171370.
|
[27] |
SELICEAN S, WANG C, GUIXÉ-MUNTET S, et al. Regression of portal hypertension: underlying mechanisms and therapeutic strategies[J]. Hepatol Int, 2021, 15(1): 36-50. DOI: 10.1007/s12072-021-10135-4.
|
[28] |
ZAFRA C, ABRALDES JG, TURNES J, et al. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis[J]. Gastroenterology, 2004, 126(3): 749-755. DOI: 10.1053/j.gastro.2003.12.007.
|
[29] |
MØLLER S, BENDTSEN F. The pathophysiology of arterial vasodilatation and hyperdynamic circulation in cirrhosis[J]. Liver Int, 2018, 38(4): 570-580. DOI: 10.1111/liv.13589.
|
[30] |
ABRALDES JG, ALBILLOS A, BAÑARES R, et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial[J]. Gastroenterology, 2009, 136(5): 1651-1658. DOI: 10.1053/j.gastro.2009.01.043.
|
[31] |
HUANG HC, TSAI MH, CHANG CC, et al. Microbiota transplants from feces or gut content attenuated portal hypertension and portosystemic collaterals in cirrhotic rats[J]. Clin Sci (Lond), 2021, 135(24): 2709-2728. DOI: 10.1042/CS20210602.
|
[32] |
WU H, YAN S, WANG G, et al. von Willebrand factor as a novel noninvasive predictor of portal hypertension and esophageal varices in hepatitis B patients with cirrhosis[J]. Scand J Gastroenterol, 2015, 50(9): 1160-1169. DOI: 10.3109/00365521.2015.1037346.
|
[33] |
WANLESS IR. The role of vascular injury and congestion in the pathogenesis of cirrhosis: the congestive escalator and the parenchymal extinction sequence[J]. Curr Hepatol Rep, 2020, 19(1): 40-53. DOI: 10.1007/s11901-020-00508-y.
|
[34] |
VERNA EC, MORELLI G, TERRAULT NA, et al. DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort[J]. J Hepatol, 2020, 73(3): 540-548. DOI: 10.1016/j.jhep.2020.03.031.
|
[35] |
JINDAL A, BHARDWAJ A, KUMAR G, et al. Clinical decompensation and outcomes in patients with compensated cirrhosis and a hepatic venous pressure gradient ≥20 mm Hg[J]. Am J Gastroenterol, 2020, 115(10): 1624-1633. DOI: 10.14309/ajg.0000000000000653.
|
[36] |
TREBICKA J, AMOROS A, PITARCH C, et al. Addressing profiles of systemic inflammation across the different clinical phenotypes of acutely decompensated cirrhosis[J]. Front Immunol, 2019, 10: 476. DOI: 10.3389/fimmu.2019.00476.
|
[37] |
MONTEIRO S, GRANDT J, USCHNER FE, et al. Differential inflammasome activation predisposes to acute-on-chronic liver failure in human and experimental cirrhosis with and without previous decompensation[J]. Gut, 2021, 70(2): 379-387. DOI: 10.1136/gutjnl-2019-320170.
|